Genes involved in atherosclerosis

Experimental Nephrology

Volumn 10, Issue 2, 2002, Pages 150-163

  Laukkanen, Johanna ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Adhesion molecules; Apoptosis; Atherosclerosis; Growth factors; Inflammation; Lipoprotein receptors; Matrix metalloproteinases

Indexed keywords

APOLIPOPROTEIN E; CD31 ANTIGEN; CD36 ANTIGEN; CELL ADHESION MOLECULE; COLLAGEN TYPE 4; COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1; INTERLEUKIN 4; LECTIN RECEPTOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR; SCAVENGER RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DISEASE COURSE; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 0036216317     PISSN: 10187782     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049910     Document Type: Article

References (164)

1. The pathogenesis of atherosclerosis: A perspective for the 1990s
2. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils
3. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II
4. A naturally occurring isoform of the human macrophage scavenger receptor (SR-A) gene generated by alternative splicing blocks modified LDL uptake
5. Gene expression in macrophage-rich human atherosclerotic lesions: 15-Lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts
6. Recent progress in defining the role of scavenger receptors in lipid transport, atherosclerosis and host defence
7. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: Marked induction of scavenger receptor and VLDL receptor expression during lesion development
8. Coexpression of type I and type II human macrophage scavenger receptors in macrophages of various organs and foam cells in atherosclerotic lesions
9. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
10. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macromolecules
11. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins
12. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors
13. Divalent cation-independent macrophage adhesion inhibited by monoclonal antibody to murine scavenger receptor
14. Class A scavenger receptors and the phagocytosis of apoptotic cells
15. Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated low-density lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells
16. Scavenger receptors mediate adhesion of activated B lymphocytes
17. The type I macrophage scavenger receptor binds to gram-positive bacteria and recognizes lipoteichoic acid
18. Recognition and plasma clearance of endotoxin by scavenger receptors
19. The macrophage scavenger receptor type A is expressed by activated macrophages and protects the host against lethal endotoxic shock
20. High affinity saturable uptake of oxidized low density lipoprotein by macrophages from mice lacking the scavenger receptor class A type I/II
21. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene
22. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice
23. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3 Leiden transgenic mice
24. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice
25. Hepatic overexpression of bovine scavenger receptor type I in transgenic mice prevents diet-induced hyperbetalipoproteinemia
26. CD36 and atherosclerosis
27. CD36 is a receptor for oxidized low density lipoprotein
28. CD36 induction on human monocytes upon adhesion to tumor necrosis factor-activated endothelial cells
29. Regulated expression of CD36 during monocyte-to-macrophage differentiation: Potential role of CD36 in foam cell formation
30. Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators
31. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells
32. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
33. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
34. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis
35. 2
36. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice
37. CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta
38. A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV (CD36)
39. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians
40. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species
41. Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy?
42. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
43. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids
44. Genetics and molecular biology of hepatic lipase
45. Hepatic lipase stimulates the uptake of high density lipoprotein cholesterol by hepatoma cells
46. Metabolism of high density lipoprotein lipids by the rat liver: Evidence for participation of hepatic lipase in the uptake of cholesteryl ester
47. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores: In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control
48. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
49. Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice
50. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene
51. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics
52. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
53. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism
54. Charting the fate of the 'good cholesterol': Identification and characterization of the high-density lipoprotein receptor SR-BI
55. An endothelial receptor for oxidized low-density lipoprotein
56. Roles of lectin-like oxidized LDL receptor-1 and its soluble forms in atherogenesis
57. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation
58. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells
59. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells
60. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells
61. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions
62. Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: Upregulated expression by TNF-alpha
63. Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells
64. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits
65. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species
66. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells
67. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) supports cell adhesion to fibronectin
68. LOX-1 supports adhesion of gram-positive and gram-negative bacteria
69. Cellular adhesion molecules and atherogenesis
70. Integrins and other cell adhesion molecules
71. Induction by IL 1 and interferon-gamma: Tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1)
72. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon
73. Deletions in the cytoplasmic domain of platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) result in changes in ligand binding properties
74. IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells
75. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies
76. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines
77. Cell surface lectins in the immune system
78. Mechanism of action and in vivo role of platelet-derived growth factor
79. Modulation of growth factor action: Implications for the treatment of cardiovascular diseases
80. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor
81. Cloning and expression of human platelet-derived growth factor alpha and beta receptors
82. Platelet-derived growth factor: Isoform-specific signalling via heterodimeric or homodimeric receptor complexes
83. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes
84. Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo
85. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty
86. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
87. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine
88. Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients
89. Endogenously elicited antibodies to platelet derived growth factor-BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit
90. Platelet-derived growth factor BB induces functional vascular anastomoses in vivo
91. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries
92. Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model
93. Antisense inhibition of basic fibroblast growth factor induces apoptosis in vascular smooth muscle cells
94. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Synergistic interaction with hypoxia
95. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model
96. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta
97. Angiogenesis, VEGF and PDGF-BB expression, iron deposition and oxidation-specific epitopes in stented human coronary arteries
98. Deactivation of macrophages by transforming growth factor-beta
99. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor
100. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro
101. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop
102. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity
103. Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets
104. Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells
105. Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells
106. In vivo effect of TGF-beta 1: Enhanced intimal thickening by administration of TGF-beta 1 in rabbit arteries injured with a balloon catheter
107. Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model
108. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions: Colocalization implicates TGF-beta in fibrofatty lesion development
109. The expression of TGF-beta receptors in human atherosclerosis: Evidence for acquired resistance to apoptosis due to receptor imbalance
110. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions
111. Aging and arteriosclerosis. I. Development of myointimal hyperplasia after endothelial injury
112. Aging and arteriosclerosis: Cell cycle kinetics of young and old arterial smooth muscle cells
113. Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-beta in vascular smooth muscle cells
114. Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions: Conversion from an antiproliferative to profibrotic response to TGF-beta 1
115. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells
116. Smooth muscle lineage diversity in the chick embryo: Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factor-beta
117. Anti-inflammatory mechanisms in the vascular wall
118. Unregulated inflammation shortens human functional longevity
119. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal
120. Chemokine receptors and their role in inflammation and infectious diseases
121. Chemokines, leukocytes, and atherosclerosis
122. Monocyte chemoattractant protein-1 in human atheromatous plaques
123. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B
124. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
125. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice
126. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice
127. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
128. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
129. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
130. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease
131. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase
132. Downregulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones
133. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
134. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
135. 2-dependent manner
136. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
137. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
138. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
139. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators
140. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
141. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
142. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
143. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
144. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis?
145. Effects of lipoxygenases on gene expression in mammalian cells
146. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein
147. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress
148. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation
149. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation
150. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture
151. Apoptosis in the vascular wall and atherosclerosis
152. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques
153. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death
154. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes
155. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells
156. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
157. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis
158. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro: TIMP-3 promotes apoptosis
159. Matrix metal-loproteinases: Implication in vascular matrix remodelling during atherogenesis
160. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
161. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells
162. Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture
163. Immune modulation of metalloproteinase production in human macrophages: Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma
164. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages